HeartSciences Inc. reported fiscal 2026 revenue of $4.3K, essentially flat with fiscal 2025, and a net loss that widened modestly to $9.142M from $8.765M a year earlier; diluted loss per share was $(3.48) for FY 2026 versus $(9.34) in FY 2025.
Financial Highlights
- Revenue was $4.3K for FY 2026, flat vs $4.35K in FY 2025 (0% YoY).
- Net income: Net loss of $9.142M for FY 2026 vs net loss of $8.765M in FY 2025 (loss widened by $377K, ≈4%).
- Diluted EPS: Loss per share, basic and diluted, $(3.48) for FY 2026 vs $(9.34) for FY 2025.
Business Highlights
- Product launch and upgrades: Released MyoVista Insights™ in May 2025 and rolled out a major v1.3 upgrade from March–June 2026 adding mobile access and an AI marketplace.
- Regulatory pathway: Submitted MyoVista wavECG™ for FDA 510(k) clearance in December 2025; the company separated its AI e' algorithm for additional development following updated clinical guidelines.
- Commercial traction: Secured first mainstream SaaS commercial deployments in May 2026 and onboarded an FDA-cleared third‑party AI through its marketplace in June 2026.
- Platform interoperability and recognition: Earned Epic Toolbox designation in March 2026 to enhance Epic integration prospects.
- R&D and accounting: R&D spending was reduced as phase 1 of MyoVista Insights™ completed; approximately $0.7M of software costs were capitalized to support SaaS commercialization.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.